» Articles » PMID: 23640520

Fluoxetine Reduces Murine Graft-versus-host Disease by Induction of T Cell Immunosuppression

Overview
Date 2013 May 4
PMID 23640520
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Serotonin reuptake inhibitors (SRIs) are widely used drugs in the treatment of depression and anxiety disorders. Although SRIs are generally regarded as safe drugs with relatively few side effects, literature suggests that high concentrations of SRIs may alter immune function. We investigated whether high-dose treatment with fluoxetine was able to suppress acute graft-versus-host disease (GvHD) in a MHC-matched, minor histocompatibility antigen mismatched murine bone marrow transplantation model. We found that high doses fluoxetine induce a significant reduction of clinical symptoms and increase survival of these animals. The amelioration of clinical GvHD was accompanied by a reduced expansion of alloreactive T cells. We further analyzed the direct in vitro effect of six SRIs on the viability and proliferation of human T cells and found an anti-proliferative and pro-apoptotic effect that was significantly larger in activated than in resting T cells. We discuss these results in the light of potential future exploration of SRIs as a novel class of T cell immunosuppressive drugs.

Citing Articles

Pre-intensive care unit use of selective serotonin reuptake inhibitors and mortality in critically ill adults with mental disorders: analysis from the MIMIC-IV database.

Gu W, Zhang L, Wang C, Zhao F, Yin H, Lyu J Transl Psychiatry. 2023; 13(1):187.

PMID: 37277344 PMC: 10241904. DOI: 10.1038/s41398-023-02487-2.


The potential action of SSRIs in the treatment of skin diseases including atopic dermatitis and slow-healing wounds.

Kiecka A, Szczepanik M Pharmacol Rep. 2022; 74(5):947-955.

PMID: 36203121 PMC: 9584846. DOI: 10.1007/s43440-022-00423-7.


Profiling Differential Effects of 5 Selective Serotonin Reuptake Inhibitors on TLRs-Dependent and -Independent IL-6 Production in Immune Cells Identifies Fluoxetine as Preferred Anti-Inflammatory Drug Candidate.

Takenaka Y, Tanaka R, Kitabatake K, Kuramochi K, Aoki S, Tsukimoto M Front Pharmacol. 2022; 13:874375.

PMID: 35814203 PMC: 9257214. DOI: 10.3389/fphar.2022.874375.


Selective serotonin reuptake inhibitor attenuates the hyperresponsiveness of TLR2 and TLR4 Th17/Tc17-like cells in multiple sclerosis patients with major depression.

Sales M, Kasahara T, Sacramento P, Rossi A, Cafasso M, Oyamada H Immunology. 2020; 162(3):290-305.

PMID: 33112414 PMC: 7884649. DOI: 10.1111/imm.13281.


Depression following graft-versus-host disease in a patient with acute lymphoblastic leukaemia: A case report.

Tsamakis K, Mueller C, Tsirigotis P, Tsiptsios D, Tsamakis C, Charakopoulos E Mol Clin Oncol. 2020; 12(3):208-211.

PMID: 32064096 PMC: 7016518. DOI: 10.3892/mco.2019.1970.


References
1.
Sanchez C . The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol. 2006; 99(2):91-5. DOI: 10.1111/j.1742-7843.2006.pto_295.x. View

2.
Taler M, Gil-Ad I, Korob I, Weizman A . The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neuroimmunomodulation. 2010; 18(2):117-22. DOI: 10.1159/000321634. View

3.
Roumestan C, Michel A, Bichon F, Portet K, Detoc M, Henriquet C . Anti-inflammatory properties of desipramine and fluoxetine. Respir Res. 2007; 8:35. PMC: 1876225. DOI: 10.1186/1465-9921-8-35. View

4.
Fevery S, Billiau A, Sprangers B, Rutgeerts O, Lenaerts C, Goebels J . CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia. 2007; 21(7):1451-9. DOI: 10.1038/sj.leu.2404720. View

5.
Hurley C, Fernandez Vina M, Setterholm M . Maximizing optimal hematopoietic stem cell donor selection from registries of unrelated adult volunteers. Tissue Antigens. 2003; 61(6):415-24. DOI: 10.1034/j.1399-0039.2003.00096.x. View